7:30 am Registration and Networking Breakfast

8:30 am Welcome and Opening Remarks Dr. Ronald Goldenberg

Session 1 | ARNIs and Heart Failure8:40 am New and ongoing analyses from PARADIGM-HF:

Why should you care? Dr. Scott Solomon

9:00 am Heart failure with preserved EF: Are we winning? Dr. Eva Lonn

9:20 am Q&A / Panel Discussion

9:40 am Refreshment Break

Session 2 | DOACS and CV Protection10:10 am DOACS and vascular protection: What are the latest evidence? Dr. John Eikelboom

10:30 am Painful legs, aching heart: Novel solutions for PAD Dr. Subodh Verma

10:50 am Q&A / Panel Discussion

Plenary Session11:10 am PCSK9i Trials – Key Learnings Dr. Eva Lonn

Session 3 | SGLT2 inhibition: Revolutionizing cardiometabolic and renal care11:30 am SGLT2i and CV protection: Back to the bench from the bedside Dr. Subodh Verma

11:50 pm SGLT2i and renal protection: Clinical implications Dr. Andrew Steele

12:10 pm Q&A / Panel Discussion

12:30 pm Lunch

Session 4 | GLP-1 Receptor Agonists and Diabetes Management1:20 pm Once-weekly GLP-1R agonists: Glycemic efficacy, weight loss

and cardio-renal benefits Dr. Ronald Goldenberg

1:40 pm GLP-1 Receptor Agonists: What are the guidelines saying? Dr. Vineeta Ahooja

2:00 pm Q&A / Panel Discussion

2:20 pm Closing Remarks

Ronald M. Goldenberg, MD, FRCPC, FACEConsultant EndocrinologistNorth York General Hospital andLMC Diabetes & EndocrinologyThornhill, ON

AGENDAFACULTY

PROGRAM CHAIRS

4GIANT STEPS IN

Friday, November 30, 2018Marriott Toronto Bloor Yorkville Hotel, 90 Bloor Street East, Toronto, ON

SGLT2 INHIBITORS | ARNIs | GLP-1 Receptor Agonists | DOACS

THE 3RD ANNUAL

Subodh Verma, MD, PhD, FRCSC, FAHACardiac Surgeon, St. Michael’s HospitalScientist, Keenan Research Centre for Biomedical Science and Li Ka Shing; Knowledge Institute of St Michael’s Hospital; Professor of Surgery and Pharmacology & Toxicology, University of TorontoCanada Research Chair in Cardiovascular Surgery Toronto, ON

John W. A. Eikelboom, MBBS, MSc, FRCPCAssociate Professor of Medicine,McMaster University,Hamilton, ON

Eva M. Lonn, MD, MSc, FRCPC, FACCProfessor, Division of Cardiology, Department of Medicine, McMaster University; Director, Vascular Research Ultrasound Laboratory, Population Health Research Institute, Hamilton, ON

Vineeta Ahooja, MD, FACC FASEThe Heart Health InstituteToronto, ON

Scott D. Solomon, MD Edward D. Frohlich Distinguished Chair; Professor of Medicine, Harvard Medical School;Director, Noninvasive CardiologyBrigham and Women’s Hospital, Boston, MA

Andrew W. Steele, MD, FRCPCNephrologist, Nephrology and Diabetes Lakeridge Health,Oshawa, ONAssistant Professor Adjunct, Queens UniversityKingston, ON

CARDIOMETABOLIC DISEASE

TO REGISTER: www.4GiantSteps.comThis program has received an educational grant from:

Bayer, Boehringer-Ingelheim Eli Lilly Alliance, Janssen, Novartis, Novo Nordisk, Sanofi